| Name | Title | Contact Details |
|---|---|---|
Dan Broom |
Senior Director, Wound Management R&D | Profile |
Stan Kaus |
Director, R&D | Profile |
Keith Huels |
Director of Finance, R&D | Profile |
Doug Lugge |
Director Research & Development | Profile |
Don Malinouskas |
VP Advanced Platforms R&D | Profile |
SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
WEX Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Gibraltar Laboratories is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.